Ovation.io and PrecisionLife team to develop drug-response biomarkers for GLP-1 therapies

GLP-1 therapies are among the fastest-growing drug classes worldwide, projected to drive a $95 billion obesity market by 2030

Surfix Diagnostics, NKI and CRCbioscreen join forces to validate biomarkers for colorectal cancer screening

Globally, colorectal cancer impacts 1.9 million people each year, standing as a leading cause of cancer mortality

Neuberg Diagnostics unveils Neubee to make preventive healthcare simpler

New digital health companion uses friendly, jargon-free communication to help users better understand reports

DrStore partners with TatvaCare to revolutionize diabetes & metabolic care in India

First patient dosed in trial of novel drug targeting limb-threatening artery disease

The trial will enroll up to 42 patients in Finland across four cohorts

Amydis bags $2.5 million NIH grant to develop first eye test for key ALS biomarker

DiaMedica bags Health Canada nod for Phase 2 preeclampsia trial

DiaMedica said it plans to launch the trial later in 2026

FDA nod to Boehringer Ingelheim’s first-line therapy for HER2-mutant lung cancer

Zongertinib is setting a new standard as the first targeted therapy for treatment naïve patients with HER2-mutant advanced non-small cell lung cancer with demonstrated efficacy

VivaMed BioPharma teams up with Syngene International to fast-track AI-driven drug programmes

The alliance directly links VivaMed’s computational drug hypotheses with Syngene’s preclinical development capabilities

Lilly’s Retevmo shows breakthrough results in early-stage lung cancer trial

The drug’s safety profile in LIBRETTO-432 aligned with previous selpercatinib studies, showing no unexpected concerns